The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 07, 2018
Filed:
Nov. 29, 2012
Applicant:
Bikam Pharmaceuticals, Inc., Lexington, MA (US);
Inventors:
Assignee:
Bikam Pharmaceuticals Inc., Cambridge, MA (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 317/70 (2006.01); C07C 211/52 (2006.01); C07C 255/54 (2006.01); C07C 255/58 (2006.01); C07D 317/46 (2006.01); C07D 317/64 (2006.01); C07D 317/66 (2006.01); C07C 211/45 (2006.01); C07C 217/84 (2006.01); C07C 323/09 (2006.01); C07C 237/30 (2006.01); C07C 33/50 (2006.01); C07C 43/215 (2006.01); C07C 43/225 (2006.01); C07C 49/237 (2006.01); C07C 49/813 (2006.01); C07C 211/46 (2006.01); C07C 255/59 (2006.01);
U.S. Cl.
CPC ...
C07C 211/52 (2013.01); C07C 33/50 (2013.01); C07C 43/215 (2013.01); C07C 43/225 (2013.01); C07C 49/237 (2013.01); C07C 49/813 (2013.01); C07C 211/45 (2013.01); C07C 211/46 (2013.01); C07C 217/84 (2013.01); C07C 237/30 (2013.01); C07C 255/54 (2013.01); C07C 255/58 (2013.01); C07C 255/59 (2013.01); C07C 323/09 (2013.01); C07D 317/46 (2013.01); C07D 317/64 (2013.01); C07D 317/66 (2013.01); C07C 2601/10 (2017.05); C07C 2601/14 (2017.05); C07C 2601/16 (2017.05); C07C 2601/18 (2017.05);
Abstract
Compounds and compositions are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.